Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

被引：0

作者：

Atkins, Michael B. ^{[1
]}

Escudier, Bernard ^{[2
]}

Mcdermott, David F. ^{[3
]}

Burotto, Mauricio ^{[4
]}

Choueiri, Toni K. ^{[5
,6
]}

Hammers, Hans J. ^{[7
]}

Plimack, Elizabeth R. ^{[8
]}

Porta, Camillo ^{[9
]}

George, Saby ^{[10
]}

Powles, Thomas ^{[11
]}

Donskov, Frede ^{[12
,13
]}

Kollmannsberger, Christian K. ^{[14
]}

Grimm, Marc-Oliver ^{[15
]}

Tomita, Yoshihiko ^{[16
]}

Rini, Brian, I ^{[17
]}

Jiang, Ruiyun ^{[18
]}

Federov, Viktor ^{[18
]}

Lee, Chung-Wei ^{[18
]}

Desilva, Heshani ^{[18
]}

Tannir, Nizar M. ^{[19
]}

Motzer, Robert J. ^{[20
]}

机构：

[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[2] Gustave Roussy, Villejuif, France

[3] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[4] Bradford Hill Clin Res Ctr, Santiago, Chile

[5] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

[6] Harvard Med Sch, Boston, MA USA

[7] UT Southwestern Kidney Canc Program, Dallas, TX USA

[8] Fox Chase Canc Ctr, Oreland, PA USA

[9] Univ Pavia, Pavia, Italy

[10] Roswell Pk Canc Inst, Buffalo, NY USA

[11] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England

[12] Univ Hosp, Cesena, Italy

[13] Southern Denmark Univ Hosp, Vejle, Denmark

[14] British Columbia Canc Agcy, Abbotsford, BC, Canada

[15] Jena Univ Hosp, Jena, Germany

[16] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan

[17] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[18] Bristol Myers Squibb, Moreton, England

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGIST | 2024年 / 29卷

关键词：

Nivolumab; Ipilimumab; CheckMate; 214; Advanced RCC; Favorable Risk;

D O I：

10.1093/oncolo/oyae181.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S17 / S18

页数：2

共 50 条

[21] Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
Tannir, Nizar M.
McDermott, David F.
Escudier, Bernard
Hammers, Hans J.
Aren, Osvaldo Rudy
Plimack, Elizabeth R.
Barthelemy, Philippe
Neiman, Victoria
George, Saby
Porta, Camillo
Powles, Thomas
Donskov, Frede
Grimm, Marc-Oliver
Amin, Asim
Tykodi, Scott S.
Tomita, Yoshihiko
Rini, Brian I.
McHenry, M. Brent
Saggi, Shruti Shally
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[22] Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Tannir, Nizar M.
Signoretti, Sabina
Choueiri, Toni K.
McDermott, David F.
Motzer, Robert J.
Flaifel, Abdallah
Pignon, Jean-Christophe
Ficial, Miriam
Frontera, Osvaldo Aren
George, Saby
Powles, Thomas
Donskov, Frede
Harrison, Michael R.
Barthelemy, Philippe
Tykodi, Scott S.
Kocsis, Judit
Ravaud, Alain
Rodriguez-Cid, Jeronimo R.
Pal, Sumanta K.
Murad, Andre M.
Ishii, Yuko
Saggi, Shruti Shally
McHenry, M. Brent
Rini, Brian, I
CLINICAL CANCER RESEARCH, 2021, 27 (01) : 78 - 86
[23] Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Antonia, S.
Gettinger, S.
Borghaei, H.
Goldman, J. W.
Brahmer, J.
Ready, N.
Gerber, D.
Chow, L.
Juergens, R.
Laurie, S.
Shepherd, F.
Li, X.
Li, A.
Geese, W.
Hellmann, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S458 - S458
[24] Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
McDermott, D. F.
Rini, B. I.
Motzer, R. J.
Tannir, N. M.
Escudier, B.
Kollmannsberger, C. K.
Hammers, H. J.
Porta, C.
George, S.
Donskov, F.
Gurney, H. P.
Grimm, M-O.
Harrison, M.
Hutson, T. E.
Doan, J.
Yang, S.
Rao, S.
Mekan, S.
Ambavane, A.
Powles, T.
ANNALS OF ONCOLOGY, 2018, 29 : 309 - 309
[25] CheckMate 214 patients who discontinued first-line Nivolumab plus Ipilimumab or sunitinib due to treatment-related adverse events
Gruenwald, V.
Tannir, N. M.
Motzer, R. J.
Plimack, E. R.
McDermott, D. F.
Barthelemy, P.
Porta, C.
George, S.
Powles, T.
Donskov, F.
Kollmannsberger, C. K.
Gurney, H.
Amin, A.
Grimm, M. -O.
Rini, B. I.
Tomita, Y.
McHenry, M. B.
Escudier, B.
Hammers, H. J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 150 - 150
[26] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
Motzer, R. J.
Rini, B., I
McDermott, D. F.
LANCET ONCOLOGY, 2020, 21 (06): : E304 - E304
[27] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
Motzer, R. J.
Rini, B., I
McDermott, D. F.
LANCET ONCOLOGY, 2020, 21 (11): : E518 - E518
[28] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
Motzer, R. J.
Rini, B., I
McDermott, D. F.
LANCET ONCOLOGY, 2019, 20 (10): : E559 - E559
[29] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial
Motzer, Robert J.
Powles, Thomas
Burotto, Mauricio
Escudier, Bernard
Bourlon, Maria T.
Shah, Amishi Y.
Suarez, Cristina
Hamzaj, Alketa
Porta, Camillo
Hocking, Christopher M.
Kessler, Elizabeth R.
Gurney, Howard
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Apolo, Andrea B.
Choueiri, Toni K.
LANCET ONCOLOGY, 2022, 23 (07): : 888 - 898
[30] CheckMate 214 Retrospective Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients With Previously Untreated Advanced Renal Cell Carcinoma With Sarcomatoid Features
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (12) : 6 - 8

← 1 2 3 4 5 →